Brief: Karolinska Development Says Portfolio Company SVF Vaccines Initiates Clinical Phase 1 Study Of Its Universal COVID-19 Vaccine
28/02/2023 16:32
Feb 28 (Reuters) - Karolinska Development AB KDEV.ST :
* KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY SVF VACCINES
INITIATES CLINICAL PHASE 1 STUDY OF ITS UNIVERSAL COVID-19
VACCINE
Source text for Eikon: ID:nGNE9BDF5B
Further company coverage: KDEV.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue